ASMANEX HFA

Mometasone

ASMANEX HFA

ICS MDI

Mometasone furoate · Organon

Clinical Reference

Active Medication & Mechanism

Mometasone furoate ICS
50 mcg, 100 mcg, or 200 mcg per actuation

Synthetic corticosteroid with potent anti-inflammatory properties. Reduces airway inflammation through suppression of inflammatory cell recruitment and cytokine production.

FDA-Approved Dosing by Indication

// approval varies by strength + age

Asthma

2/3 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
100 mcg	Patients ≥12 years (previously on bronchodilators alone or ICS)	2 inhalations twice daily Recommended starting dose for patients previously on bronchodilators alone or ICS therapy.	400 mcg	FDA Approved
200 mcg	Patients ≥12 years (previously on oral corticosteroids)	2 inhalations twice daily Maximum recommended dose. For patients previously on oral corticosteroids.	800 mcg	FDA Approved
Any strength	Acute bronchospasm	—	—	Not Approved Not a bronchodilator. Not for acute bronchospasm. Use a SABA.

100 mcg FDA Approved

Pop · Patients ≥12 years (previously on bronchodilators alone or ICS)

2 inhalations twice daily

Recommended starting dose for patients previously on bronchodilators alone or ICS therapy.

Total · 400 mcg
200 mcg FDA Approved

Pop · Patients ≥12 years (previously on oral corticosteroids)

2 inhalations twice daily

Maximum recommended dose. For patients previously on oral corticosteroids.

Total · 800 mcg
Any strength Not Approved

Pop · Acute bronchospasm

—

Total · — Not a bronchodilator. Not for acute bronchospasm. Use a SABA.

Acute Use

0/1 approved regimens

Strength	Population	Dose & Frequency	Total Daily	Status
Any strength	Acute bronchospasm / rescue	—	—	Not Approved Not for acute relief. Use a SABA.

Any strength Not Approved

Pop · Acute bronchospasm / rescue

—

Total · — Not for acute relief. Use a SABA.